Event Highlights
News from Bayer
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
July 09, 2021
Not intended for U.S. and UK Media
U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes
June 23, 2021
Not intended for U.S. and UK Media
Vericiguat approved in Japan to treat patients with chronic heart failure
Discover More Investor Resources
